Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.74 |
| ▸ | LMNA | P02545 | 1/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | TRPA1 | O75762 | 6/20 | 0.60 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | PORCN | Q9H237 | 2/20 | 0.56 |
| ▸ | ABL1 | P00519 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18166628 | 0.91 | MAPT (0.74) | MAPTSMN1; SMN2LMNAKMT2ATRPA1 | |
| SCHEMBL3266103 | 0.90 | MAPT (0.79) | MAPTSMN1; SMN2LMNAKMT2ATRPA1 | |
| SCHEMBL18166556 | 0.90 | MAPT (0.73) | MAPTSMN1; SMN2LMNAKMT2ATRPA1 | |
| SCHEMBL18166704 | 0.90 | MAPT (0.73) | MAPTSMN1; SMN2LMNAKMT2ATRPA1 | |
| SCHEMBL18166626 | 0.89 | MAPT (0.77) | MAPTSMN1; SMN2LMNAKMT2ATRPA1 | |
| SCHEMBL18166566 | 0.89 | MAPT (0.75) | MAPTSMN1; SMN2LMNAKMT2ATRPA1 | |
| SCHEMBL10114087 | 0.89 | MAPT (1.00) | MAPTSMN1; SMN2LMNATRPA1RXFP1 | |
| SCHEMBL3249487 | 0.88 | MAPT (1.00) | MAPTSMN1; SMN2LMNATRPA1RXFP1 | |
| SCHEMBL3248648 | 0.88 | MAPT (0.80) | MAPTSMN1; SMN2LMNAKMT2ATRPA1 | |
| SCHEMBL18166617 | 0.88 | SMN1; SMN2 (0.79) | MAPTSMN1; SMN2LMNAKMT2ATRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3663295-A1 | 2,6-DIOXO,-2,3-DIHYDRO-1H-PURINE COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO THE ACTIVITY OF THE TRPA1 CHANNEL | ELI LILLY AND CO. (US) | 2020-06-10 | — | — | EP | claimed |
| EP-3663295-A1 | 2,6-DIOXO,-2,3-DIHYDRO-1H-PURINE COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO THE ACTIVITY OF THE TRPA1 CHANNEL | ELI LILLY AND CO. (US) | 2020-06-10 | — | — | EP | disclosed |
| EP-3184527-A1 | 2,6-DIOXO,-2,3-DIHYDRO-1H-PURINE COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO THE ACTIVITY OF THE TRPA1 CHANNEL | Hydra Biosciences, Inc. (US) | 2017-06-28 | — | — | EP | disclosed |
| EP-2170309-B1 | 2,6-DIOXO,-2,3-DIHYDRO-1H-PURINE COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO THE ACTIVITY OF THE TRPA1 CHANNEL | HYDRA BIOSCIENCES INC (US) | 2016-10-26 | — | — | EP | disclosed |
| US-9073955-B2 | 2-amino-4-arylthiazole compounds as TRPA1 antagonists | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2015-07-07 | — | — | US | disclosed |
| US-8889862-B2 | 2-amino-4-arylthiazole compounds as TRPA1 antagonists | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2014-11-18 | — | — | US | disclosed |
| US-20140051667-A1 | 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AS TRPA1 ANTAGONISTS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2014-02-20 | — | — | US | disclosed |
| US-20140045865-A1 | 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AS TRPA1 ANTAGONISTS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2014-02-13 | — | — | US | disclosed |
| US-8592398-B2 | 2-amino-4-arylthiazole compounds as TRPA1 antagonists | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2013-11-26 | — | — | US | disclosed |
| EP-2655377-A1 | 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AS TRPA1 ANTAGONISTS | Glenmark Pharmaceuticals S.A. (CH) | 2013-10-30 | — | — | EP | disclosed |
| US-20130165454-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WAREFARE AGENT-INDUCED INJURIES | HYDRA BIOSCIENCES, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130165454-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WAREFARE AGENT-INDUCED INJURIES | HYDRA BIOSCIENCES, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| WO-2012085662-A1 | 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AS TRPA1 ANTAGONISTS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2012-06-28 | — | — | WO | disclosed |
| US-20120157411-A1 | 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AS TRPAI ANTAGONISTS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157411-A1 | 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AS TRPAI ANTAGONISTS | TRPA1, TRPV1, TRPV2 | MAPT 857/4885SMN1; SMN2 3713/4885LMNA 2576/4885 |
| US-20130165454-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CHEMICAL WAREFARE AGENT-INDUCED INJURIES | CASP3, MGMT, ELANE | MAPT 1662/4885SMN1; SMN2 2791/4885LMNA 930/4885 |
| US-20140045865-A1 | 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AS TRPA1 ANTAGONISTS | TRPA1, TRPV1, TRPV2 | MAPT 864/4885SMN1; SMN2 2464/4885LMNA 2966/4885 |
| US-20140051667-A1 | 2-AMINO-4-ARYLTHIAZOLE COMPOUNDS AS TRPA1 ANTAGONISTS | TRPA1, TRPV1, TRPV2 | MAPT 864/4885SMN1; SMN2 2464/4885LMNA 2966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.